Is the medicinal cannabis market is a promising investment option?

Medicinal cannabis investments are looking like an increasingly promising one to add to your portfolio as the market is predicted to rise by almost 20% CAGR over the next five years.

To be specific, according to research by the Market Research Future team, the medicinal cannabis market will be worth over $33 million by 2027, which is an increase of 18.4%.

Medicinal cannabis is derived from the cannabis plant and treats some medical conditions that impact a persons quality of life physically or psychologically.

A great deal of research is being done to determine its effects on even more conditions in the hope that it can reduce the need for more addictive medications such as opioids.

What can medicinal cannabis be used for?

Cannabis used to treat conditions is not a new thing. It has been used in many different cultures worldwide for generations. It is only in recent years been given a bad reputation as a recreational drug.

Medicinal cannabis has been found to improve many symptoms and the quality of life for many people. It is currently being prescribed to those referred to a specialist consultant for very specific conditions such as epilepsy and MS.

There are several conditions that medicinal cannabis is showing promise in treating, such as chronic pain, arthritis, Alzheimer’s, glaucoma, depression, PTSD and diabetes, to name a few.

Cannabis has now been legalised in many countries to either be prescribed for medical conditions or the purpose of research and testing on different conditions for its therapeutic effects.

Who are the significant companies for investments?

The global medicinal cannabis market is growing at an incredible rate, not surprising considering this is an exciting emerging market. Getting in at the start is the smart move to make.

These are just a few of the companies that have had significant investments made and are now leading the way:

  • Jazz Pharmaceuticals (USA)
  • Canopy Growth Corporation (Canada)
  • Cannabis Sativa, Inc. (USA)
  • GW Pharmaceuticals (UK)
  • Canndoc (Israel)
  • Emerald Health Therapeutics (Canada)
  • Aphria (Canada)
  • Medical Marijuana, Inc (USA)

Governments, businesses and corporate organisations are all investing in and funding cannabis research for medical use. It is this collective input that’s helping to drive the growth and something that must continue.

Why is everyone investing in medicinal cannabis?

Medical cannabis is such a good investment because we are just at the tip of the iceberg in terms of what this medication can do.

Compared to many other medications available for the same conditions and symptoms, medicinal cannabis appears to be the safer choice with less unsavoury side effects.

In the world of pharmaceuticals, medicinal cannabis seems to be a game changer and has the power to do great things where others have caused more harm than good.

As many look to make more ethical investments, cannabis could be the ideal place to put your money and help improve future generations’ well-being and welfare in doing so.

Which countries dominate the medicinal cannabis market?

It is clear that America and Canada are the global leaders and have the lion’s share of the market. This is because of the legalisation of medicinal cannabis across most states and relaxed recreational laws in some states.

Cannabis is becoming more widely accepted and decriminalised in some respects across European countries. Europe also has a sizable chunk of the market and is now the second largest next to North America.

Thanks to greater investments in research, manufacturing and production, the medicinal cannabis market is set to continue its growth, and who knows, it could even grow far beyond what’s being predicted.